Neumora Therapeutics, Inc. Common Stock (NMRA)
NMRA Stock Price Chart
Explore Neumora Therapeutics, Inc. Common Stock interactive price chart. Choose custom timeframes to analyze NMRA price movements and trends.
NMRA Company Profile
Discover essential business fundamentals and corporate details for Neumora Therapeutics, Inc. Common Stock (NMRA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 Sept 2023
Employees
110.00
Website
https://www.neumoratx.comCEO
Daljit Singh Aurora
Description
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
NMRA Financial Timeline
Browse a chronological timeline of Neumora Therapeutics, Inc. Common Stock corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.23.
Earnings released on 7 May 2026
EPS came in at -$0.30 surpassing the estimated -$0.32 by +6.25%.
Earnings released on 16 Mar 2026
EPS came in at -$0.35 falling short of the estimated -$0.34 by -2.94%.
Earnings released on 6 Nov 2025
EPS came in at -$0.35 falling short of the estimated -$0.34 by -2.94%.
Earnings released on 6 Aug 2025
EPS came in at -$0.33 surpassing the estimated -$0.38 by +13.16%.
Earnings released on 12 May 2025
EPS came in at -$0.42 falling short of the estimated -$0.40 by -5.00%.
Earnings released on 3 Mar 2025
EPS came in at -$0.37 surpassing the estimated -$0.46 by +19.57%.
Earnings released on 12 Nov 2024
EPS came in at -$0.45 falling short of the estimated -$0.38 by -18.42%.
Earnings released on 6 Aug 2024
EPS came in at -$0.37 matching the estimated -$0.37.
Earnings released on 7 May 2024
EPS came in at -$0.34 surpassing the estimated -$0.35 by +2.86%.
Earnings released on 7 Mar 2024
EPS came in at -$0.71 falling short of the estimated -$0.65 by -9.23%.
Earnings released on 1 Nov 2023
EPS came in at -$1.14 falling short of the estimated -$0.36 by -216.67%.
Earnings released on 30 Jun 2023
EPS came in at -$0.25 .
Earnings released on 31 Mar 2023
EPS came in at -$0.23 .
Earnings released on 31 Dec 2022
EPS came in at -$0.19 .
Earnings released on 30 Sept 2022
EPS came in at -$0.19 .
Earnings released on 30 Jun 2022
EPS came in at -$0.20 .
Earnings released on 31 Mar 2022
EPS came in at -$0.28 .
Earnings released on 31 Dec 2021
EPS came in at -$0.18 .
Earnings released on 30 Sept 2021
EPS came in at -$1.17 .
NMRA Stock Performance
Access detailed NMRA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
